InsiderSignal.AI

InsiderSignal.ai

NTRA - Natera, Inc.

Insider Sale by Moshkevich Solomon (Pres, CLINICALDIAGNOSTICS)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

3 days ago, Moshkevich Solomon, serving as Pres, CLINICALDIAGNOSTICS at Natera, Inc. (NTRA), sold 3,000 shares at $202.30 per share, for a total transaction value of $606,899.00. Following this transaction, Moshkevich Solomon now holds 147,882 shares of NTRA.

This sale represents a 2.00% decrease in Moshkevich Solomon's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Wednesday, April 1, 2026 and publicly disclosed via SEC Form 4 filing on Friday, April 3, 2026, 2 days after the trade was made.

Natera, Inc. operates in the HEALTHCARE sector, specifically within the DIAGNOSTICS & RESEARCH industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Moshkevich Solomon

Moshkevich Solomon

Pres, CLINICALDIAGNOSTICS

Solomon Moshkevich is the President of Clinical Diagnostics at Natera, Inc., a global leader in cell-free DNA testing[[1]](https://investor.natera.com/news/news-details/2023/Natera-Announces-Senior-Leadership-Appointments/default.aspx). He joined Natera in 2011 and has been instrumental in developing and commercializing the company's cell-free DNA product portfolio, including Panorama, Prospera, and Signatera[[1]](https://investor.natera.com/news/news-details/2023/Natera-Announces-Senior-Leadership-Appointments/default.aspx). Prior to his current role, Moshkevich served as general manager of oncology beginning in 2019, overseeing significant expansion of Signatera, Natera's molecular residual disease test, and leading efforts to achieve Medicare coverage across multiple cancer types[[1]](https://investor.natera.com/news/news-details/2023/Natera-Announces-Senior-Leadership-Appointments/default.aspx). He has also been actively involved in advancing the company's use of artificial intelligence and machine learning, collaborating with clinical researchers to develop AI-assisted tools for extracting and visualizing cancer patient data[[2]](https://oncodaily.com/voices/solomon-moshkevich-438810). Moshkevich began his career as a management consultant at Bain & Company in New York before transitioning to private equity with the investment team at Parthenon Capital in Boston[[1]](https://investor.natera.com/news/news-details/2023/Natera-Announces-Senior-Leadership-Appointments/default.aspx). He holds a B.A. in economics and mathematics from Columbia University, which he completed summa cum laude, and an M.B.A. from Stanford University[[1]](https://investor.natera.com/news/news-details/2023/Natera-Announces-Senior-Leadership-Appointments/default.aspx). As of January 2026, Moshkevich directly owned 123,499 shares of Natera common stock[[3]](https://www.investing.com/news/insider-trading-news/natera-inc-president-moshkevich-sells-675k-in-stock-93CH-4433882).

View full insider profile →

Trade Price

$202.30

Quantity

3,000

Total Value

$606,899.00

Shares Owned

147,882

Trade Date

Wednesday, April 1, 2026

3 days ago

SEC Filing Date

Friday, April 3, 2026

Filed 2 days after trade

HEALTHCAREDIAGNOSTICS & RESEARCH

About Natera, Inc.

Company Overview

No company information available
View news mentioning NTRA

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5339552

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime